Intellia Therapeutics (NASDAQ:NTLA) Hits New 52-Week Low at $19.77

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) shares hit a new 52-week low on Thursday . The stock traded as low as $19.77 and last traded at $19.92, with a volume of 306701 shares. The stock had previously closed at $21.17.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on NTLA. Wolfe Research began coverage on shares of Intellia Therapeutics in a research note on Thursday, February 15th. They set a "peer perform" rating on the stock. Wedbush reaffirmed a "neutral" rating and set a $29.00 target price on shares of Intellia Therapeutics in a research note on Tuesday. Canaccord Genuity Group upped their target price on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the stock a "buy" rating in a research note on Friday, February 23rd. Finally, The Goldman Sachs Group cut shares of Intellia Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $136.00 to $32.00 in a report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, Intellia Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $67.00.

Intellia Therapeutics Trading Down 5.4 %

The firm's fifty day moving average price is $26.64 and its 200-day moving average price is $27.62. The firm has a market cap of $1.93 billion, a price-to-earnings ratio of -3.70 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.01. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. The business had revenue of ($1.92) million during the quarter, compared to analysts' expectations of $15.10 million. During the same quarter in the prior year, the business posted ($1.40) EPS. On average, sell-side analysts expect that Intellia Therapeutics, Inc. will post -5.58 earnings per share for the current year.

Insider Activity at Intellia Therapeutics

In related news, EVP James Basta sold 2,297 shares of the company's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $32.99, for a total value of $75,778.03. Following the completion of the sale, the executive vice president now owns 81,571 shares in the company, valued at approximately $2,691,027.29. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 3.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Intellia Therapeutics

A number of large investors have recently bought and sold shares of NTLA. Harbor Capital Advisors Inc. raised its position in Intellia Therapeutics by 18.7% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 16,604 shares of the company's stock worth $525,000 after buying an additional 2,610 shares during the last quarter. Commonwealth Equity Services LLC raised its position in Intellia Therapeutics by 6.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 30,415 shares of the company's stock worth $962,000 after buying an additional 1,910 shares during the last quarter. Chevy Chase Trust Holdings LLC raised its position in Intellia Therapeutics by 3.0% during the 3rd quarter. Chevy Chase Trust Holdings LLC now owns 1,002,955 shares of the company's stock worth $31,713,000 after buying an additional 29,412 shares during the last quarter. Raymond James & Associates raised its position in Intellia Therapeutics by 49.3% during the 3rd quarter. Raymond James & Associates now owns 104,374 shares of the company's stock worth $3,300,000 after buying an additional 34,458 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its position in Intellia Therapeutics by 21.1% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 31,970 shares of the company's stock worth $1,011,000 after buying an additional 5,574 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.